Last reviewed · How we verify

NCT04680156

Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)

Terminated Last updated 30 December 2022
What this trial tests

trial testing Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies in Adhesive Capsulitis in 120 participants. Terminated before completion.

Timeline
17 December 2020
Primary endpoint
12 September 2022
12 September 2022

Quick facts

Lead sponsorEndo Pharmaceuticals
StatusTerminated
Study typeOBSERVATIONAL
Enrollment120
Start date17 December 2020
Primary completion12 September 2022
Estimated completion12 September 2022
Sites30 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Endo Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Adhesive Capsulitis or Frozen Shoulder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a long-term follow-up study to evaluate the safety and durability (efficacy) of response to EN3835 compared to placebo in participants who were treated in EN3835-210 or the pivotal Phase 3 parent studies for the treatment of AC of the shoulder (frozen shoulder).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Adhesive Capsulitis

Currently open trials in the same condition.

Other Endo Pharmaceuticals trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04680156.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing